Abstract：Pompe disease, also called type Ⅱ glycogen storage disease, is a rare autosomal recessive inherited disease caused by the storage of glycogen in lysosome due to acid α-glucosidase (GAA) defciency, with the most severe conditions in the skeletal muscle, the myocardium, and the smooth muscle. Patients may have the manifestations of dyspnea and dyskinesia, with or without hypertrophic cardiomyopathy. GAA gene mutation has ethnic and regional differences, and new mutation sites are found with the advances in research. Gene analysis is the gold standard for the diagnosis of Pompe disease. Conventional methods, such as skin and muscle biopsies and dried blood spot test, have certain limitations for the diagnosis of this disease. In recent years, prenatal diagnosis and newborn screening play an important role in early diagnosis of this disease. Enzyme replacement therapy (ERT) has a satisfactory effect in the treatment of this disease, but it may lead to immune intolerance. New targeted gene therapy and modified ERT will be put into practice in the future. This article reviews the research advances in the diagnosis and treatment of Pompe disease.
Avula S, Nguyen TM, Marble M, et al. Cardiac response to enzyme replacement therapy in infantile Pompe disease with severe hypertrophic cardiomyopathy[J]. Echocardiography, 2017, 34(4):621-624.
[2]
Malhotra K, Carrington DC, Liebeskind DS. Restrictive arteriopathy in late-onset Pompe disease:case report and review of the literature[J]. J Stroke Cerebrovasc Dis, 2017, 26(8):e1722-e1725.
[3]
Broomfield A, Fletcher J, Davison J, et al. Response of 33 UK patients with infantile-onset Pompe disease to enzyme replacement therapy[J]. J Inherit Metab Dis, 2016, 39(2):261-271.
[4]
Kishnani PS, Hwu WL, Mandel H, et al. A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease[J]. J Pediatr, 2006, 148(5):671-676.
[5]
Quan JJ, Liu LJ, Lyu TW, et al. Atypical infantile-onset Pompe disease with hypertrophic cardiomyopathy[J]. Chin Med J (Engl), 2017, 130(19):2393-2394.
[6]
Tarnopolsky M, Katzberg H, Petrof BJ, et al. Pompe disease:diagnosis and management. Evidence-based guidelines from a Canadian expert panel[J]. Can J Neurol Sci, 2016, 43(4):472-485.
Martínez M, Romero MG, Guereta LG, et al. Infantile-onset Pompe disease with neonatal debut:a case report and literature review[J]. Medicine, 2017, 96(51):e9186.
[9]
Chan J, Desai AK, Kazi ZB, et al. The emerging phenotype of late-onset Pompe disease:A systematic literature review[J]. Mol Genet Metab, 2017, 120(3):163-172.
[10]
Jones HN, Crisp KD, Robey RR, et al. Respiratory muscle training (RMT) in late-onset Pompe disease (LOPD):effects of training and detraining[J]. Mol Genet Metab, 2016, 117(2):120-128.
[11]
Chu YP, Sheng B, Lau KK, et al. Clinical manifestation of late onset Pompe disease patients in Hong Kong[J]. Neuromuscul Disord, 2016, 26(12):873-879.
[12]
Forsha D, Li JS, Smith PB, et al. Cardiovascular abnormalities in late-onset Pompe disease and response to enzyme replacement therapy[J]. Genet Med, 2011, 13(7):625-631.
[13]
Mori M, Bailey LA, Estrada J, et al. Severe cardiomyopathy as the isolated presenting feature in an adult with late-onset Pompe disease:a case report[J]. JIMD Rep, 2017, 31:79-83.
[14]
Walczak-Galezewska M, Skrypnik D, Szulinska M, et al. Lateonset Pompe disease in a 54 year-old sportsman with an episode of syncope:a case report[J]. Eur Rev Med Pharmacol Sci, 2017, 21(16):3665-3667.
[15]
Fukuhara Y, Fuji N, Yamazaki N, et al. A molecular analysis of the GAA gene and clinical spectrum in 38 patients with Pompe disease in Japan[J]. Mol Genet Metab Rep, 2017, 14:3-9.
[16]
Musumeci O, La MG, Spada M, et al. LOPED study:looking for an early diagnosis in a late-onset Pompe disease high-risk population[J]. J Neurol Neurosurg Psychiatry, 2016, 87(1):5-11.
[17]
Oba-Shinjo SM, da Silva R, Andrade FG, et al. Pompe disease in a Brazilian series:clinical and molecular analyses with identifcation of nine new mutations[J]. J Neurol, 2009, 256(11):1881-1890.
[18]
Matsuoka T, Miwa Y, Tajika M, et al. Divergent clinical outcomes of alpha-glucosidase enzyme replacement therapy in two siblings with infantile-onset Pompe disease treated in the symptomatic or pre-symptomatic state[J]. Mol Genet Metab Rep, 2016, 9:98-105.
[19]
Ünver O, Hacıfazlıoğlu NE, Karatoprak E, et al. The frequency of late-onset Pompe disease in pediatric patients with limbgirdle muscle weakness and nonspecific hyperCKemia:A multicenter study[J]. Neuromuscul Disord, 2016, 26(11):796-800.
[20]
Hu J, Sun L, Ren W, et al. Two novel mutations in the gene that codes for acid α-glucosidase in a baby with Pompe disease[J]. Eur Heart J, 2015, 36(14):883.
[21]
Sifi Y, Medjroubi M, Froissart R, et al. Clinical analysis of Algerian patients with Pompe disease[J]. J Neurodegener Dis, 2017, 2017(2):1-7.
[22]
Arslan A, Poyrazoğlu HG, Kiraz A, et al. Combination of two different homozygote mutations in Pompe disease[J]. Pediatr Int, 2016, 58(3):241-243.
[23]
Dolfus C, Simon JP, Landemore G, et al. Combination of acid phosphatase positivity and rimmed vacuoles as useful markers in the diagnosis of adult-onset Pompe disease lacking specifc clinical and pathological features[J]. Folia Neuropathol, 2016, 54(3):295-302.
[24]
Schoser B, Stewart A, Kanters S, et al. Survival and long-term outcomes in late-onset Pompe disease following alglucosidase alfa treatment:a systematic review and meta-analysis[J]. J Neurol, 2017, 264(4):621-630.
[25]
Golsari A, Nasimzadah A, Thomalla G, et al. Prevalence of adult Pompe disease in patients with proximal myopathic syndrome and undiagnosed muscle biopsy[J]. Neuromuscul Disord, 2018, 28(3):257-261.
[26]
Kronn DF, Day-Salvatore D, Hwu WL, et al. Management of confirmed newborn-screened patients with Pompe disease across the disease spectrum[J]. Pediatrics, 2017, 140(Suppl 1):S24-S45.
[27]
Pascarella A, Terracciano C, Farina O, et al. Vacuolated PASpositive lymphocytes as an hallmark of Pompe disease and other myopathies related to impaired autophagy[J]. J Cell Physiol, 2018, 23(8):5829-5837.
[28]
Wens SC, Schaaf GJ, Michels M, et al. Elevated plasma cardiac troponin T levels caused by skeletal muscle damage in Pompe disease[J]. Circ Cardiovasc Genet, 2016, 9(1):6-13.
[29]
Yang CF, Yang CC, Liao HC, et al. Very early treatment for infantile-onset Pompe disease contributes to better outcomes[J]. J Pediatr, 2016, 169:174-80.
Tsai AC, Hung YW, Harding C, et al. Next generation deep sequencing corrects diagnostic pitfalls of traditional molecular approach in a patient with prenatal onset of Pompe disease[J]. Am J Med Genet A, 2017, 173(9):2500-2504.
[32]
Hwang HE, Hsu TR, Lee YH, et al. Muscle ultrasound:a useful tool in newborn screening for infantile onset Pompe disease[J]. Medicine, 2017, 96(44):e8415.
[33]
van Gelder CM, Poelman E, Plug I, et al. Effects of a higher dose of alglucosidase alfa on ventilator-free survival and motor outcome in classic infantile Pompe disease:an open-label single-center study[J]. J Inherit Metab Dis, 2016, 39(3):383-390.
[34]
Ripolone M, Violano R, Ronchi D, et al. Effects of short-to-long term enzyme replacement therapy (ERT) on skeletal muscle tissue in late onset Pompe disease (LOPD)[J]. Neuropathol Appl Neurobiol, 2017 Jun 2. doi:10.1111/nan.12414.[Epub ahead of print].
[35]
Desai AK, Walters CK, Cope HL, et al. Enzyme replacement therapy with alglucosidase alfa in Pompe disease:Clinical experience with rate escalation[J]. Mol Genet Metab, 2018, 123(2):92-96.
[36]
van der Ploeg AT, Clemens PR, Corzo D, et al. A randomized study of alglucosidase alfa in late-onset Pompe's disease[J]. N Engl J Med, 2010, 362(15):1396-1406.
Case LE, Bjartmar C, Morgan C, et al. Safety and effcacy of alternative alglucosidase alfa regimens in Pompe disease[J]. Neuromuscul Disord, 2015, 25(4):321-332.
[39]
Chien YH, Hwu WL, Lee NC, et al. Albuterol as an adjunctive treatment to enzyme replacement therapy in infantile-onset Pompe disease[J]. Mol Genet Metab Rep, 2017, 11:31-35.
[40]
Basile I, Da Silva A, El Cheikh K, et al. Effcient therapy for refractory Pompe disease by mannose 6-phosphate analogue grafting on acid α-glucosidase[J]. J Control Release, 2018, 269:15-23.
